Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
In the SUSTAIN 1-7 series of clinical trials which investigated the effectiveness of once weekly semaglutide injections for the treatment of diabetic and obese patients, semaglutide consistently demonstrated significant reductions in HbA1c levels compared to placebo and other usual diabetes medications (metformin, sitagliptin, dulaglutide)
Several mechanisms explain why semaglutide may cause headaches
Optional escalation to 2 mg if HbA1c remains above target: The diabetes protocol stops at 1 mg for most patients because that dose produces near-maximal HbA1c reduction (1.8 percentage points on average)
Avoid vigorous shaking, which can damage peptide chains
Body adjusting, side effects improving Month 3 (4mg): Additional 6-8 lbs
US$ 22.07
US$ 25.41
US$ 20.22
US$ 20.50
